Skip to main content

Table 1 Characteristics of the 77 patients of tigecycline-treated pneumonia involving multidrugresistant Acinetobacter baumannii (MDRAB)

From: Clinical experience with tigecycline in the treatment of hospital-acquired pneumonia caused by multidrug resistant Acinetobacter baumannii

Characteristics

values

Demographic parameters

 Age, mean ± SD, years

62.1 ± 17.0

 Male/Female

52/25

Comorbidities

 Hepatic dysfunction

2 (2.6%)

 Renal insufficiency

7 (9.1%)

 Chronic pulmonary disease

24 (31.2%)

 Heart disease

14 (18.2%)

 Hypertension

17 (22.1%)

 Diabetes mellitus

6 (7.8%)

 Immune compromise

5 (6.5%)

 multiple organ failure

3 (3.9%)

 Malignancy

8 (10.4%)

 Surgery

16 (20.8%)

Clinical conditions

 CURB65 score, mean ± SD

2.0 ± 1.0

 Mechanical ventilation

48 (62.3%)

Susceptibility tests of initial airway MDRAB isolates

 With sensitive to tigecycline

42 (54.5%)

 With sensitive to sulbactam

7 (9.1%)

Tigecycline treatment

 Duration, mean ± SD, days

11.69 ± 6.11

 Combination therapy

71 (92.2%)

  With sulbactam

64 (90.1%)

  With carbapenems

4 (5.6%)

  With amikacin

1 (1.4%)

  With fluoroquinolones

4 (5.6%)

Delayed tigecycline treatment

21 (27.3%)

  1. Abbreviations: SD standard deviation